Key points from article :
A new startup Elevian got 5.5$ from investors for “death disruption” scene.
Drugs based on GDF11 could treat Alzheimer’s, coronary heart disease, age-related muscle dysfunction.
GDF11 injected on its own, made old mice stronger, increased blood flow to their brains.
In 2016, Ambrosia company launched the first human trial of young plasma transfusions.
Young blood could improve memory and learning in older rodents.
Even a short course of weekly plasma infusions could improve some of the Alzheimer’s symptoms.
The study was published in Science journal.
